San Diego Business Journal


Recent and archived news stories on: Biotechnology, Doctors, Drugs, Health Insurance, HMO's/PPO's, Hospitals, Medical Devices, Nursing...

PURE Bioscience, Roka Bioscience to Combine Marketing Efforts

El Cajon-based PURE Bioscience has partnered with Roka Bioscience in a combined marketing effort, expanding PURE’s reach to Roka’s entire customer base.

By Brittany Meiling July 10, 2017 12:08 p.m. share »

TrovaGene Escapes Delisting From Nasdaq

Local biotech TrovaGene Inc. is back in line with the Nasdaq rules, meaning — for the time being — the company won’t get delisted from the public market.

By Brittany Meiling July 10, 2017 11:59 a.m. share »
Tease photo

Scripps, Qualcomm Prepare ACO Offering

Scripps Health’s recent agreement with Qualcomm Inc. to build and manage a customized medical network represents San Diego’s boldest step yet toward a Medicare-born model that holds health care providers financially accountable for lowering costs and improving care.

By John Cox July 6, 2017 12:44 p.m. share »
Tease photo

FDA Approval Puts Illumina in Clinic

Illumina Inc., the quiet giant making instruments for the world’s scientists, just got the OK from federal regulators to bring its technology out of the laboratory and into the clinic.

By Brittany Meiling July 6, 2017 12:41 p.m. share »

FDA Grants Special Status to Evofem Drug

A product being developed by local biotech Evofem Biosciences has received a high priority classification from regulators, granting the company a number of perks.

By Brittany Meiling July 5, 2017 12:39 p.m. share »
Tease photo

Three Local Startups Recognized as Tech Innovators

Three San Diego startups were named winners of a tech innovation contest by global media company Red Herring.

By Brittany Meiling July 4, 2017 1:24 p.m. share »

Eloxx Pharmaceuticals Raises $6 Million

Eloxx Pharmaceuticals, a subsidiary of La Jolla’s Sevion Therapeutics Inc., has raised $6 million.

By Brittany Meiling July 4, 2017 1:06 p.m. share »

Sorrento Therapeutics Gets FDA OK for Human Trials of Non-Opioid Pain Treatment

Local drugmaker Sorrento Therapeutics Inc. just got the OK from regulators to start human trials for a non-opioid medicine that might treat chronic pain.

By Brittany Meiling June 30, 2017 12:10 p.m. share »

Imprimis to Focus on Ophthalmology, Sells Pennsylvania Facility and Some Assets

San Diego’s Imprimis Pharmaceuticals is selling off some assets and closing a facility in Pennsylvania as part of a move to focus its research pipeline.

By Brittany Meiling June 30, 2017 11:56 a.m. share »

Earley Departs Red Cross, Joins West Health

Bill Earley has been named chief administration officer and general counsel of West Health, a group of nonprofit organizations dedicated to helping seniors successfully age in place with affordable, high-quality health and support services.

By Sarah de Crescenzo June 29, 2017 3:58 p.m. share »

AristaMD's Founder Leaves Company

Rebecca Cofinas, founder and CEO of San Diego's AristaMD, has left the digital health company.

By Sarah de Crescenzo June 29, 2017 3:51 p.m. share »

S.D.’s Reputation Draws 2 Canadian Biotechs to Town

Two Canadian biotechnology companies — both of which are developing cancer treatments — opened offices in San Diego last week.

By Brittany Meiling June 29, 2017 2:51 p.m. share »

Former Company's Drug, CEO Back in S.D. With New Firm

A drug whose failure led local biotech Celladon Corp. to fold in 2015 is coming back to San Diego, and in the hands of a former Celladon executive.

By Brittany Meiling June 29, 2017 1:21 p.m. share »

FDA Clears Quidel Corp.'s Diagnostic Test

Quidel Corp. got the green light to sell a new diagnostic test that can detect a respiratory virus in children.

By Brittany Meiling June 29, 2017 10:51 a.m. share »

Imprimis Well-Positioned for Generic Drugs Push

Federal support for more competition among drugmakers may be a boon for San Diego-based Imprimis Pharmaceuticals Inc., a maker of generic drugs meant to compete with pricier pharmaceuticals.

By Brittany Meiling June 28, 2017 4:58 p.m. share »